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ABSTRACT
Objective To determine if use of paracetamol in early life
is an independent risk factor for childhood asthma.
Design Prospective birth cohort study.
Setting Melbourne Atopy Cohort Study.
Participants 620 children with a family history of allergic
disease,withparacetamoluseprospectivelydocumented
on18occasionsfrombirthto2yearsofage,followeduntil
age 7 years.
Main outcome measures The primary outcome was
childhoodasthma,ascertainedby questionnaireat 6 and
7 years. Secondary outcomes were infantile wheeze,
allergic rhinitis, eczema, and skin prick test positivity.
Results Paracetamol had been used in 51% (295/575) of
children by 12 weeks of age and in 97% (556/575) by
2 years. Between 6 and 7 years, 80% (495/620) were
followed up; 30% (148) had current asthma. Increasing
frequencyofparacetamolusewasweaklyassociatedwith
increased risk of childhood asthma (crude odds ratio
1.18, 95% confidence interval 1.00 to 1.39, per doubling
of days of use). However, after adjustment for frequency
of respiratory infections, this association essentially
disappeared(odds ratio1.08, 0.91to 1.29).Paracetamol
use for non-respiratory causes was not associated with
asthma (crude odds ratio 0.95, 0.81 to 1.12).
Conclusions In children with a family history of allergic
diseases, no association was found between early
paracetamol use and risk of subsequent allergic disease
after adjustment for respiratory infections or when
paracetamol use was restricted to non-respiratory tract
infections. These findings suggest that early paracetamol
use does not increase the risk of asthma.
INTRODUCTION
Paracetamol (acetaminophen) is the most commonly
usedanalgesicinyoungchildren.
1Someevidencesug-
gests that ingestion of paracetamol in early life may
cause asthma, eczema, and allergic rhinitis in some
children.
2-7 Exposure to paracetamol may increase
respiratory oxidative stress by depleting glutathione
in the lungs,
8 thereby enhancing airway inflammation
and bronchoconstriction.
2 Decreased glutathione
concentrations may also induce a shift from a T helper
cell type 1 response to a T helper cell type 2 response
with cytokine production favouring the development
ofallergic disease.
9Given the currentglobalburden of
asthma,
10 if paracetamol is a cause of asthma its use
needs to be urgently re-evaluated, particularly in the
first two years of life during pulmonary
development.
11
The largest study to consider this question was the
International Study of Asthma and Allergy in Child-
hood (ISAAC) phase III, which included data from
72 countries. It showed that exposure to paracetamol
in the first year of life was associated with an increased
risk of asthma at age 6-7 years (odds ratio adjusted for
sex, region of the world, language, and gross national
income: 1.46, 95% confidence interval 1.36 to 1.56),
allergic rhinitis (1.48, 1.38 to 1.60), and eczema (1.35,
1.26 to 1.45).
7 However, the results from ISAAC may
have been confounded by respiratory infections in
earlylife.Respiratoryinfectionsarecommonlytreated
with paracetamol,
1 and a history of respiratory infec-
tions,particularlylowerrespiratorytractinfections,isa
known risk factor for asthma.
12-16 In addition, the
ISAAC findings may have been affected by recall
bias
17; both the outcome of asthma and paracetamol
exposure in the first year of life were measured when
the child was 7 years old. Parents of children with
asthma are possibly more likely to report use of para-
cetamol in early life.
18 Moreover, the researchers did
not assess the dose-response relation between expo-
sure to paracetamol and risk of allergic disease, which
would help to substantiate a causal argument.
19
In a birth cohort of infants at high risk of developing
atopic conditions, we analysed whether use of para-
cetamolininfancyinfluencedthesubsequentdevelop-
ment of asthma and allergic diseases according to
indication for use.
METHODS
Study population
The Melbourne Atopy Cohort Study recruited 620
infants before birth, between 1990 and 1994 in
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enrolled if one or more of their first degree family
members had eczema, asthma, allergic rhinitis, or
severe food allergy. The recruitment process has
beendescribedinmoredetailelsewhere.
20Allmothers
gave informed consent.
Data collection
After the birth of the infant, an allergy trained nurse
(CA) did a telephone survey every four weeks until
the age of 64 weeks and then at 78 weeks and at
2 years (a total of 18 times). Each survey documented
any illnesses since the previous interview and oral
exposurestofoodormedicine,includingparacetamol.
The number of episodes, the days of use, and the rea-
son for the administration of paracetamol were
recorded for each exposure. An annual telephone
interview took place from 3 to 7 years of age
Oneofthreeallergytrainedresearchnursesdidskin
prick tests at 6, 12, and 24 months, using a standard
technique.
21. Allergen extracts used were cows’ milk,
egg white, peanut, house dust mite, rye grass, and cat
dander (Bayer, Spokane, WA, USA), and tests were
read at 15-20 minutes.
Definitions
Total days of paracetamol use
We recorded the number of days of exposure to para-
cetamolforeachchild(regardlessofdoseorfrequency
per day) within the first two years of life. This included
exposure to any preparation that contained para-
cetamol. Each child potentially had from zero to a
maximum of 730 (2×365) “total days” of paracetamol
use in the first two years of life.
Indication for paracetamol use
Weclassifiedthereasonforuseofparacetamolforeach
episode of illness for each child into one of four cate-
gories (table 1). We partitioned the total days of para-
cetamol use into these categories and assigned each
child a value for days of exposure for each category
(zero if never given for any illness in that category).
We also collected parental report of contact with
medical professionals for four different kinds of infec-
tion (otitis media, upper respiratory tract infection,
bronchitis, and gastroenteritis) 18 times in the first two
years of life, regardless of treatment with paracetamol.
Childhood outcomes
We based the following definitions for childhood out-
comes on parental report from telephone interviews
whenchildrenwere aged6or 7years.Wedefinedcur-
rent childhood asthma as one or more episodes of
asthma diagnosed by the family physician in the pre-
vious 12 months. This was the primary outcome. We
defined current childhood eczema as one or more epi-
sodes of eczema diagnosed by the family physician in
theprevious12months.Wedefinedcurrentchildhood
allergic rhinitis as one or more episodes of nasal dis-
charge or congestion, in the absence of an upper
respiratory tract infection, in the previous 12 months,
which either the family physician or parent attributed
to allergic rhinitis (hay fever) and which was treated
with an antihistamine, a nasal steroid, or both.
22
We used the following definitions for outcomes
within the first two years of life. Infantile eczema was
a parental report of either a doctor’s diagnosis of
eczema or any rash that was treated with a topical ster-
oid preparation (excluding rash that affected only the
scalpornappyregion).
23Infantile wheezewasaparen-
talreportofadoctor’sdiagnosisofanasthma-likecon-
ditionbefore2yearsofage.Wedefineda positiveskin
prick test as a weal of at least 3 mm (mean) in diameter
to any allergen with a positive (histamine) control.
Statistical analysis
We comparedtotal days of paracetamol use in the first
two years of life, for any cause and for each category,
between children who developed asthma and those
whodidnotdevelopasthma.Becauseofskeweddistri-
butions, we report medians and interquartile ranges
along with Mann-Whitney tests.
Next, we used logistic regression models to estimate
associations between total paracetamol use (regardless
of indication for use) and risk of each allergic disease
outcome.Weusedtotalepisodesofexposureandtotal
days of paracetamol use as potential continuous pre-
dictors. We applied a log (base 2) transformation
(with an offset of 1 added) for days of paracetamol
exposure,allowinginterpretationofthecorresponding
odds ratios as the effect of doubling the days of use of
paracetamol. For the outcomes at 6 and 7 years of age,
we used generalised estimating equations to enable a
single combined analysis with outcome data from 6
and 7 years, with allowance for repeated measures.
15
Wemadeadjustmentsforknownpotentialconfoun-
ders: infant’s sex, parental history of asthma or
eczema, and presence of older siblings at the time of
birth,all determinedatrecruitmentduring pregnancy.
The final model adjusted for the frequency of medical
contact for infections (otitis media, upper respiratory
tract infection, bronchitis, and gastroenteritis).
Todetermineiftheindicationforuseofparacetamol
affected the association with each of the outcomes, we
restrictedtheaboveanalysistoeachspecificindication
for which paracetamol was used. We used days of use
Table 1 |Classification of indications for exposure to paracetamol
Category Description of indications
1 Lower respiratory tract
symptoms
Episodes of paracetamol exposure due to lower respiratory tract
infection, asthma, wheeze of any cause, bronchitis, bronchiolitis, or
croup, regardless of any other concomitant reasons for administration
2 Eczema/allergy Episodes of paracetamol exposure due to eczema or food reaction,
regardlessofanyotherconcomitantreasonsincategory3or4.Although
paracetamol is not recommended for these conditions, some parents
reported using paracetamol for these conditions
3 Upper respiratory tract
symptoms
Episodes of paracetamol exposure due to upper respiratory tract
infection, otitis media, tonsillitis, or throat infection, regardless of any
other concomitant reasons in category 4
4 Non-respiratory illness Episodesofparacetamolexposureduetogastroenteritis,conjunctivitis,
fever without associated evidence of respiratory tract infection,
immunisations, or physical injury. This was the form of exposure of
primary interest
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uous predictors in logistic regression models. We
madeadjustmentsforconfoundersasdescribedabove.
RESULTS
Study population and paracetamol exposure
Of the 620 infants in the Melbourne Atopy Cohort
Study, 575 (92.7%) were followed to age 2 years (25
were lost to follow-up, 14 refused participation, and
six were missed at 2 years but rejoined the study after
thistime).Atotalof495(79.8%)completedafollow-up
at either 6 or 7 years or both (88 lost, 37 refused parti-
cipation). Children who were lost to follow-up were
not systematically different in terms of exposure to
paracetamol or early signs of allergic disease (infantile
wheeze, eczema, and skin prick test reactivity) (data
available on request). Details of the demographics of
the Melbourne Atopy Cohort have been previously
reported.
20
Almost all (97%, 556/575) infants received para-
cetamol during the first two years of life (table 2).
The median age at first exposure was 12 (interquartile
range 12-20) weeks (fig 1). Of the children exposed to
paracetamolwithinthefirsttwoyears,themediantotal
number of days of exposure was 17 (10-27). Most chil-
dren (537) were exposed to paracetamol for non-
respiratory illnesses (table 2), and the next most com-
mon indication was upper respiratory tract infections.
Weak correlations existed between the days of use for
each of the indications (highest Spearman’s ρ=0.22).
Total episodes of exposure and cumulative days of
exposure were highly correlated (Spearman ρ ranged
from 0.81 to 0.89). As the findings with respect to asso-
ciations between the two measures of paracetamol
exposure and the outcomes were similar, we report
onlytheassociationswithcumulativedaysofexposure.
Frequency of outcomes
The cumulative incidence of eczema up to 2 years of
age was 45.9% (264/575). At age 6-7, 29.9% (148/495)
of children had current childhood asthma, 23.6%
(117/495) had current allergic rhinitis, and 31.8%
(157/493) had current childhood eczema. Skin prick
tests were done on 445 children at 2 years of age, and
30.3% (135/445) reacted to one or more allergens.
Total days of paracetamol use
Thetotalnumberofdaysofparacetamoluseinthefirst
twoyearsoflifewasslightlyhigherinchildrenwhohad
current childhood asthma or allergic rhinitis (fig 2,
table 3). The unadjusted regression analysis showed
thatagreaternumberofdaysofparacetamolexposure
(allcauses)wasassociatedwithincreasingriskofchild-
hoodasthma(oddsratio1.18,95%confidenceinterval
1.00 to 1.39 per doubling of days of paracetamol use)
(table 4). We also found an association for the out-
comes of allergic rhinitis and infantile wheeze but no
clear evidence of associations with eczema or skin
prick test positivity at 2 years of age (table 4). Adjust-
ment for standard confounders (table 4, model 2) did
not alter the observed associations. However, adjust-
ment for frequency of medical contact for infections,
particularly frequency of respiratory tract infections,
attenuated the strength of the association with child-
hood asthma (table 4, model 3), leaving no evidence
of an independent association.
Paracetamol use for non-respiratory illness
We found no evidence of any association between
paracetamol use for non-respiratory illness (category
4) and risk of any allergic disease outcome (tables 3
and 5, fig 2).
Paracetamol use for lower respiratory tract illness
Use of paracetamol for lower respiratory tract symp-
toms (category 1) was strongly associated with
increased risk of childhood asthma (odds ratio 1.49,
1.25 to 1.78, per doubling of days) (table 3, fig 2).
Two hundred and forty-four children had lower
respiratorytract symptoms(infantilewheeze, bronchi-
tis, or drugs for lower respiratory tract symptoms). In
thissubgroup,43%(104/244)hadreceivedatleastone
Table 2 |Paracetamol intake up to 2 years of age according to stated reason for use (n=575)
Reason for use
No(%)children
exposed
Episodes of exposure* Cumulative days of exposure*
Median (IQR) Range Median (IQR) Range
Any indication 556 (96.7) 7 (4-9) 1-16 17 (10-27) 1-84
Lower respiratory tract symptoms 104 (18.1) 1 (1-1) 1-5 4 (2-5) 1-27
Allergy 13 (2.3) 1 (1-1) 1-2 2 (2-3) 1-8
Upper respiratory tract symptoms 510 (88.7) 3 (2-5) 1-12 9 (5-16) 1-69
Non-respiratory illness 537 (93.4) 3 (2-5) 1-11 7 (4-11) 1-50
IQR=interquartile range.
*Calculated in children exposed to paracetamol for each reason.
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Fig 1 | Age at first introduction of paracetamol (with 95%
confidence interval)
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toms. When we restricted the analysis to the subgroup
who had lower respiratory tract symptoms, we found
minimalevidencethatanyuse(oddsratio1.16,0.68to
1.98)orfrequentuse(1.12,0.91to1.38perdoublingof
days) of paracetamol for lower respiratory tract symp-
toms was associated with increased risk of childhood
asthma.
Paracetamol use for upper respiratory tract illness
Paracetamol use for upper respiratory tract symptoms
(category3)wasassociatedwithincreasedriskofchild-
hood asthma (odds ratio 1.20, 1.05 to 1.38, per dou-
bling of days) (table 3). Only 2.4% of children (14/
575) did not have upper respiratory tract symptoms
within the first two years of life. The number of events
of upper respiratory tract symptoms was strongly
related to increased risk of childhood asthma (35%,
14% to 61%, per event). When we adjusted the days
of paracetamol use for upper respiratory tract symp-
tomsforthenumberofevents,theevidenceofanasso-
ciationwassubstantiallyattenuated(1.10,0.95to1.28).
DISCUSSION
Consistent with previous studies in this area,
72425this
prospective cohort study found evidence of a crude
association between paracetamol use in early life and
increased risk of asthma. However, we found no evi-
dence of such an association after adjustment for his-
tory of early infections, nor when the association was
limitedto paracetamoluse fornon-respiratorytract ill-
ness.Moreover,althoughuseofparacetamolforlower
respiratory tract infections and wheeze was associated
with increased risk of allergic disease, increasing days
of use for these indications did not increase the risk of
allergic disease. We conclude that paracetamol use in
early life is not an independent risk factor for child-
hood asthma.
As the vast majority of the children in this cohort
were exposed to at least one dose of paracetamol, we
wereunabletoassessifanyversusnoexposuretopara-
cetamol was associated with an increased risk of child-
hood asthma; instead we examined the effect of
increasing frequency of exposure to paracetamol.
However, as the primary biological hypothesis pre-
sented to explain why paracetamol may increase the
risk of asthma implies a dose-response relation,
269 our
finding of no dose-response relation is important evi-
dence against a causal association.
Although we have shown that the association
between paracetamol in early life and increased risk
of childhood asthma is inflated by confounding by
indication, we cannot completely rule out the possibi-
lity of a weak association. For the outcome of asthma,
our data are consistent (95% confidence interval) with
anadjustedoddsratiobetween0.76and1.26forasub-
stantial increase in paracetamol exposure for non-
respiratory indications (exposure shifted from 4 days
(25th centile) to 11 days (75th centile), based on the
adjusted odds ratio in table 5). For total paracetamol
Table 3 |Paracetamol use in early life among children with and without childhood asthma and allergic rhinitis. Values are
medians (interquartile range) unless stated otherwise
Reason for use
Asthma at age 6-7 years Allergic rhinitis at age 6-7 years
No (n=347) Yes (n=148) P value* No (n=378) Yes (n=117) P value*
Any indication 16 (9-25) 18 (10.5-29) 0.05 16 (9-26) 19 (12-31) 0.01
Lower respiratory tract symptoms 0 (0-0) 0 (0-2) <0.01 0 (0-0) 0 (0-3) <0.01
Upper respiratory tract symptoms 7 (3-14) 9 (4-17) 0.04 8 (3-14) 10 (5-17) 0.01
Non-respiratory illness 6 (3-10) 6 (3-10) 0.53 6 (3-10) 6 (3-9) 0.48
*Mann-Whitney U tests.
Table 4 |Associations between total days of paracetamol use (any indication) during early life and risk of allergic disease
Unadjusted
Model 2—adjusted
for standard confounders*
Model 3—adjusted
for frequency of infections†
Odds ratio(95% CI) P value Odds ratio (95%CI) P value Odds ratio (95%CI) P value
Early life (up to 2 years) outcomes
Infantile wheeze 1.45 (1.23 to 1.71) <0.01 1.44 (1.21 to 1.71) <0.01 1.44 (1.17 to 1.77) <0.01
Infantile eczema 1.13 (0.99 to 1.30) 0.08 1.16 (1.01 to 1.33) 0.04 1.13 (0.97 to 1.31) 0.11
Positive skin prick test‡ 0.97 (0.82 to 1.14) 0.68 0.96 (0.81 to 1.13) 0.62 0.98 (0.82 to 1.18) 0.86
Childhood (5-7 years) outcomes
Asthma 1.18 (1.00 to 1.39) 0.05 1.16 (0.98 to 1.38) 0.09 1.08 (0.91 to 1.29) 0.39
Incident asthma§ 0.94 (0.75 to 1.18) 0.60 0.96 (0.76 to 1.22) 0.73 0.97 (0.76 to 1.25) 0.83
Allergic rhinitis 1.21 (1.01 to 1.46) 0.04 1.19 (0.99 to 1.44) 0.07 1.17 (0.96 to 1.43) 0.12
Eczema 1.05 (0.90 to 1.22) 0.52 1.09 (0.93 to 1.27) 0.29 1.10 (0.93 to 1.29) 0.26
Associations expressed as effect per doubling of number of days of intake (regression on log2 (days paracetamol+1)).
*Infant’s sex, parental history of asthma, and presence of older siblings at time of birth.
†As per model 2, plus frequency of infections (upper and lower respiratory tract infections, otitis media, and gastrointestinal infections) during first
2 years of life (frequency of each form of infection classified as 0, 1-2, or ≥3).
‡≥3 mm to at least one of six allergens at 2 year test.
§Excludes children who had lower respiratory symptoms within first 2 years of life.
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of the interquartile range, the 95% confidence interval
for the adjusted odds ratio for the same outcome was
0.87 to 1.44.
Strengths and limitations of study
The data from this study have several important
strengths in assessing the relation between exposure
to paracetamol in early life and risk of childhood aller-
gic conditions. The prospective design, with frequent
assessment of exposures and early signs of allergic dis-
ease, eliminated the potential for recall bias that could
occurinretrospectivedesigns.Recordingoftheindica-
tion for use made it possible to infer the presence of
confounding by indication in these crude associations.
Therateoffollow-upinthisstudywasgood(80%ofthe
cohort),particularlygiventhesevenyearstudyperiod.
The sampling frame for the Melbourne Atopy
Cohort Study is both a strength and limitation. As
only children with a family history of allergic disease
were recruited, these results should be extrapolated to
thegeneralpopulationwithcare.Thebenefitsofstudy-
ing infants at high risk are that the outcomes are more
common, which increases the relative power of the
study, and that infants at high risk are of particular
interest as a potential target group for interventions to
prevent the development of allergic diseases.
The study has several limitations in assessing the
associations between paracetamol intake and risk of
allergic disease. The design is observational in nature,
so untangling the effects of use of paracetamol and
respiratory tract infections is difficult, as the presence
of these factors is highly positively correlated. How-
ever, the adjusted associations indicate that a history
of respiratory tract symptoms, rather than exposure
to paracetamol, is more likely to be the true risk factor
for allergic disease. We have also examined whether
use of paracetamol for respiratory illness increases
the risk of a child developing asthma compared with
those who were not treated with paracetamol; we
found no evidence to support this (although the
power to detect such effects was limited in this study).
Although we have not been able to have a physician’s
assessment of asthma in this cohort at age 6 or 7, we
have shown excellent agreement between the ISAAC
definition of asthma that is widely used in epidemiolo-
gical research and that used in this study (κ=0.80, 95%
confidence interval 0.70 to 0.91, unpublished data).
The measures of asthma and rhinitis rely on parental
report,buttheseshouldbereasonablyspecific,asonly
symptoms confirmed by a doctor were included.
Nevertheless, some mild cases of asthma may have
been missed. Also, we were not able to routinely do
skinpricktestsattheageof6or7yearsonthechildren
inthisstudy,sowecannotassessifparacetamolinearly
life influences risk of atopy (including atopic asthma)
later in childhood. Finally, this study assessed only
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Fig 2 | Days of paracetamol use (by indication) between
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Table 5 |Associations between paracetamol intake for non-respiratory causes during early life and risk of allergic disease
later in childhood
Unadjusted
Model 2—adjusted
for standard confounders*
Model 3—adjusted
for frequency of infections†
Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Early life (up to 2 years) outcomes
Infantile wheeze 0.92 (0.80 to 1.07) 0.28 0.92 (0.79 to 1.07) 0.29 1.07 (0.88 to 1.29) 0.51
Infantile eczema 1.01 (0.88 to 1.16) 0.89 1.03 (0.90 to 1.19) 0.67 1.04 (0.90 to 1.21) 0.58
Positive skin prick test‡ 0.95 (0.80 to 1.13) 0.58 0.95 (0.80 to 1.14) 0.60 0.99 (0.82 to 1.19) 0.93
Childhood (5 to 7 years) outcomes
Asthma 0.95 (0.81 to 1.12) 0.58 0.95 (0.80 to 1.12) 0.55 0.98 (0.83 to 1.17) 0.85
Incident asthma§ 0.94 (0.73 to 1.21) 0.63 0.96 (0.74 to 1.24) 0.74 0.97 (0.74 to 1.28) 0.85
Allergic rhinitis 1.10 (0.92 to 1.32) 0.28 1.09 (0.91 to 1.31) 0.36 1.13 (0.93 to 1.37) 0.23
Eczema 0.98 (0.84 to 1.15) 0.81 1.00 (0.86 to 1.18) 0.97 1.03 (0.87 to 1.21) 0.75
Associations expressed as effect per doubling of number of days of intake (regression on log2 (days paracetamol+1)).
*Infant’s sex, parental history of asthma, and presence of older siblings at time of birth.
†As per model 2, plus frequency of infections (upper and lower respiratory tract infections, otitis media, and gastrointestinal infections) during first
2 years of life (frequency of each form of infection classified as 0, 1-2, or ≥3).
‡≥3 mm to at least one of six allergens at 2 year test.
§Excludes children who had lower respiratory symptoms within first 2 years of life.
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groups have implicated exposure to paracetamol dur-
ing pregnancy or in later childhood as a risk factor for
asthma,
7242728butwecannotcommentontheeffectsof
exposure at these times.
Conclusions and policy implications
Several authors have called for a randomised trial to
determine if exposure to paracetamol in early life
increases the risk of allergic disease.
2629 The logistical
problems with such a study would be substantial, as
children would need to be followed until at least
7 years of age for a reliable assessment of the outcome
of asthma. Use of a placebo control would be ethically
fraught, and widespread non-compliance and contam-
ination of the placebo arm would potentially occur.
Use of ibuprofen as a control may be possible, but
any observed effect could be due to a beneficial effect
of ibuprofen rather than paracetamol increasing the
riskofallergicdisease.Thelackofassociationbetween
use of paracetamol for non-respiratory tract infections
and all forms of allergic disease outcomes in this study
makes it unlikely that paracetamol is a true cause of
allergic disease in otherwise well children.
The apparent association between frequent con-
sumption of paracetamol in early life and increased
risk of asthma reported in other studies can be
explained as confounding by indication (treatment of
respiratory infections with paracetamol). This study
does not provide any evidence to suggest that para-
cetamol is a cause of allergic disease.
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